|
Since Henry Kaplan and Saul Rosenberg first used radiation to treat Hodgkin’s disease in the 1960s, Stanford researchers and clinicians have helped to define the standard of care for lymphomas worldwide. Today the Lymphoma and Hodgkin’s Disease Research Program continues this legacy through interdisciplinary investigations into immune system cancer and its molecular and genetic origins.
Transforming their discoveries into clinical advances, program researchers and clinicians work closely to bring new diagnostics and treatments into the patient care setting to improve patient outcome at all stages of disease.
Their efforts have introduced a number of important advances, including the first FDA-approved monoclonal antibody for cancer treatment (Rituxan), custom vaccines tailor made from proteins found only on a patient’s cancer cells and new gene-based diagnostics that predict which patients should be singled out for more aggressive treatment.
Program members are involved in the following research areas:
 |
With more than 40 years of lymphoma research and patient care at Stanford, the program draws upon a number of important assets, including:
| • |
a large and diverse patient population, with more than 6,000 adult and pediatric visits |
| • |
a tissue bank containing 5,500 fresh frozen lymphoma specimens |
| • |
a clinical database offering diagnostic results, treatment and outcomes for more than 10,000 lymphoma and 5,000 Hodgkin’s disease patients. |
|
|
|
Lymphoma Pathogenesis
Diagnostic and therapeutic profiling of lymphoma subtypes
Novel Diagnostics and Immunotherapeutics
Phase II and Phase III Clinical Trials
Cancer Survivorship Studies
Cutaneous Lymphomas
Program Directors
Ron Levy, MD
Sandra Horning, MD
|
